MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results